Memantin Tad (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium entry caused by glutamate over‑activation. This reduces excitotoxic neuronal damage, helping to preserve neuronal function and slow the progression of cognitive decline associated with Alzheimer’s disease.

The appropriate dose of Memantin Tad is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions exactly.

Safety data for memantine during pregnancy and lactation are limited, and the pregnancy category is listed as unknown. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Memantin Tad, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantin Tad belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While acetylcholinesterase inhibitors enhance cholinergic transmission, memantine reduces excitotoxic glutamate activity. Both classes may be used together in some treatment regimens to target different disease pathways.

Memantin Tad should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Memantin Tad is taken orally, usually as a tablet swallowed with water. The exact timing and frequency are set by the prescriber, who may start with a low dose and gradually increase it to the target maintenance dose based on tolerability.

Serious risks include seizures, severe allergic reactions such as anaphylaxis, hallucinations or psychosis, and cardiac arrhythmias. Patients should be monitored for these events, and any sudden or severe symptoms should prompt immediate medical attention.

Memantin Tad is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists, as these conditions increase the risk of adverse effects.